NRC vs. ASTH, CTOS, RDWR, WLDN, PRG, ETWO, EVH, TIXT, NXTT, and YEXT
Should you be buying National Research stock or one of its competitors? The main competitors of National Research include Astrana Health (ASTH), Custom Truck One Source (CTOS), Radware (RDWR), Willdan Group (WLDN), Aaron's (PRG), E2open Parent (ETWO), Evolent Health (EVH), Telus Digital (TIXT), Next Technology (NXTT), and Yext (YEXT). These companies are all part of the "business services" industry.
National Research vs. Its Competitors
National Research (NASDAQ:NRC) and Astrana Health (NASDAQ:ASTH) are both small-cap business services companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.
47.3% of National Research shares are owned by institutional investors. Comparatively, 52.8% of Astrana Health shares are owned by institutional investors. 8.1% of National Research shares are owned by company insiders. Comparatively, 20.0% of Astrana Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
National Research has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500. Comparatively, Astrana Health has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.
Astrana Health has higher revenue and earnings than National Research. National Research is trading at a lower price-to-earnings ratio than Astrana Health, indicating that it is currently the more affordable of the two stocks.
In the previous week, Astrana Health had 7 more articles in the media than National Research. MarketBeat recorded 9 mentions for Astrana Health and 2 mentions for National Research. National Research's average media sentiment score of 1.71 beat Astrana Health's score of 0.54 indicating that National Research is being referred to more favorably in the media.
National Research has a net margin of 17.14% compared to Astrana Health's net margin of 1.56%. National Research's return on equity of 71.33% beat Astrana Health's return on equity.
Astrana Health has a consensus target price of $53.29, indicating a potential upside of 128.99%. Given Astrana Health's stronger consensus rating and higher probable upside, analysts clearly believe Astrana Health is more favorable than National Research.
Summary
Astrana Health beats National Research on 10 of the 16 factors compared between the two stocks.
Get National Research News Delivered to You Automatically
Sign up to receive the latest news and ratings for NRC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
National Research Competitors List
Related Companies and Tools
This page (NASDAQ:NRC) was last updated on 7/25/2025 by MarketBeat.com Staff